Difference between Patoladigana Vasti versus standard control Triphala Kwath Lekhan Vasti in the management of Dyslipidemia Medoroga

Evaluation of Comparative Efficacy of Patoladi Vasti versus Triphala Kwath Lekhan Vasti in the Management of Medoroga (Dyslipidemia) : A Randomized Controlled Trial - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062741

Enrollment

Registered

2024-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E889- Metabolic disorder, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Newly Diagnosed Dyslipedemia Patients with Serum Cholesterol > 20 mg/dl Serum Triglycerides > 150 mg/dl Serum HDL > 40 mg/dl Serum VLDL > 30 mg/dl Patient with Controlled Hypertension Patient with Controlled type II Diabetes

Exclusion criteria

Exclusion criteria: Patients with age 60 years Serum Triglycerides > 150 mg/dl Serum HDL Serum VLDL < 30 mg/dl

Design outcomes

Primary

Measure	Time frame
to asses the efficacy of Patoladi Vasti in Serum total Cholesterol level Triglycerides LDL HDL VLDLTimepoint: 7 Weeks	—

Secondary

Measure	Time frame
to asses the efficacy of triphala kwath lekhan Vasti in Serum total Cholesterol level Triglycerides LDL HDL VLDLTimepoint: 1 week 7th week	—

Countries

India

Contacts

Public ContactDr Shruti Dhok

Mahatma Gandhi Ayurveda College Hospital and Research Centre Salod Wardha

shweta.parwe@dmimsu.edu.in9403142270

Outcome results